SGO 2023 Annual Meeting on Women’s Cancer
Mansoor R. Mirza, MD, on Endometrial Cancer: New Findings on Dostarlimab-gxly Plus Chemotherapy
Mansoor R. Mirza, MD, of Copenhagen’s Rigshospitalet, discusses phase III data from the ENGOT-EN6-NSGO/GOG-3031/RUBY study, which showed that, compared with carboplatin and paclitaxel alone, dostarlim...
Ursula A. Matulonis, MD, on Ovarian Cancer: New Data on Niraparib From the ENGOT-OV16/NOVA Trial
Ursula A. Matulonis, MD, of Dana-Farber Cancer Center discusses the ENGOT-OV16/NOVA study, which initially showed that niraparib maintenance therapy significantly prolonged progression-free survival i...
Shannon N. Westin, MD, MPH, on Ovarian Cancer: Results From the NOW Trial of Neoadjuvant Olaparib in BRCA-, PALB-, or RAD51C–Mutant Disease
Shannon N. Westin, MD, MPH, of The University of Texas MD Anderson Cancer Center, discusses results from the NOW study, which showed that neoadjuvant olaparib is feasible and has a good safety profile...
Shannon N. Westin, MD, MPH, on Endometrial and Ovarian Cancers: New Data on Selumetinib and Olaparib From the SOLAR Trial
Shannon N. Westin, MD, MPH, of The University of Texas MD Anderson Cancer Center, discusses new findings on the combination of olaparib and selumetinib, which benefited patients with RAS-mutant ovaria...
